2012 Researcher Matthew Hebb

HSP27 as a New Molecular Target in Glioblastoma

matthew hebb brain tumour researcher

Matthew Hebb
Western University: London, Ontario


What does the title mean?

The study is looking at heat shock proteins as a potential new therapeutic target in glioblastoma multiforme tumours. 

Project Summary:

Glioblastoma multiforme (GBM) is a deadly brain cancer that remains without effective treatment. There isa critical need to identify new molecular targets in order to advance our understanding and treatment ofGBM.

Heat shock protein 27 (HSP27) is overexpressed in systemic cancers and in brain tumors, and provides unwanted protection to tumor cells that promotes their replication, spread and resistance to treatment. Numerous studies are ongoing to evaluate drugs that inhibit this protein in systemic cancers but little advancement has been made in the brain.

We have recently shown that HSP27 inhibitors markedly increase the sensitivity of GBM cell lines to chemotherapy, similar to that which has been reported in pancreatic, lung, breast, colon and other cancers.

The objective of this study is to now test these agents in fresh GBM cells obtained directly from neurosurgical patients. These efforts have important implications as an essential next step in determining the potential of HSP27 as a new therapeutic target in GBM.

Research Outcome:

This proof-of-concept study evaluated the antitumor impact of a direct electrical stimulation technique, termed intratumoral modulation therapy (IMT) on glioblastoma (GBM) cells. Materials and Methods: An in vitro IMT model comprised of a calibrated electrode to deliver continuous, low-intensity stimulation within GBM preparations. Viability and apoptosis assays were performed in treated immortalized and patient-derived GBM cells, and postmitotic neurons. IMT was delivered alone and with temozolomide, or gene silencing of the tumor-promoting chaperone, heat-shock protein 27 (HSP27). Results: GBM cells, but not neurons, exhibited >40% loss of viability, caspase-3 activation and apoptosis with IMT. Cell death was modest with temozolomide alone (30%) but increased significantly with concomitant IMT (70%). HSP27 silencing alone produced 30% viability loss, with significant enhancement of target knockdown and GBM cell death (65%), when combined with IMT. Conclusion: These findings warrant further evaluation of IMT as a potential novel therapeutic strategy for GBM.  Read more...


Share This

Featured Story

Courtney’s Story of Stability

Stability. It’s a strange concept when you have what it known to be a progressive, life long illness. You hear the words, “Your tumour growth is stable” and for a moment you think someone is playing the world’s worst prank on you.

Learn more


Stephen's Story: "I have faith that we will meet again"

Stephen and I chatted on what should have been his 32nd Wedding Anniversary. Stephen and Susan were married for 30 years and were best...

Learn more

Tommy's Story: Fellowship recipient

Dr. Tommy Alain, the very first research Fellow funded by Brain Tumour Foundation of Canada through the William Donald Nash Brain...

Learn more

Upcoming Events

  • 23/Jan/2018: Groupe de soutien virtuel: Un groupe de soutien virtuel pour personnes touchées par une tumeur... Learn more >
  • 25/Jan/2018: Virtual Support Group East: Virtual Support Group for Eastern Canada... Learn more >
  • 25/Jan/2018: Sarnia Support Group: Meets at St. Giles Presbyterian Church,770 Lakeshore Road Sarnia, ON... Learn more >
  • 29/Jan/2018: Greater Sudbury Support Group: Meets at The Parkside Centre, 140 Durham Street, Sudbury, Ontario... Learn more >
View All Events >
Thank you to the donors whose contributions make this website and all programs, services and research possible.

Copyright © 2018 Brain Tumour Foundation of Canada. Charitable Registration #BN118816339RR0001
35 Years